Neurocrine Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
NBIX Nasdaq 2836 www.neurocrine.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Neurocrine Biosciences, Inc.

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist - Jun 30th, 2025 2:05 pm
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea - Jun 27th, 2025 6:30 am
CPRX vs. NBIX: Which Stock Is the Better Value Option? - Jun 23rd, 2025 9:40 am
Exploring 3 High Growth Tech Stocks In The US Market - Jun 20th, 2025 11:38 am
Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia - Jun 20th, 2025 6:30 am
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer - Jun 9th, 2025 2:05 pm
CPRX or NBIX: Which Is the Better Value Stock Right Now? - Jun 3rd, 2025 9:40 am
Neurocrine Biosciences' Ingrezza to Meet Fiscal 2025 Sales Outlook, RBC Capital Says - Jun 2nd, 2025 10:31 am
Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia - Jun 2nd, 2025 6:30 am
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - May 30th, 2025 2:30 pm
Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched - May 28th, 2025 10:03 pm
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - May 28th, 2025 2:05 pm
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting - May 16th, 2025 6:30 am
Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia - May 16th, 2025 6:25 am
Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont) - May 15th, 2025 2:05 pm
GRFS or NBIX: Which Is the Better Value Stock Right Now? - May 15th, 2025 9:40 am
Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia - May 14th, 2025 2:05 pm
Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside Potential - May 13th, 2025 1:48 pm
Investors Can Find Comfort In Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Quality - May 12th, 2025 4:49 am
Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - May 8th, 2025 12:59 pm